Answers are grounded in this paper and cite their sources.
Large bone defects represent one of the most challenging problems orthopedic surgeons encounter in clinical practice. Conventional methods struggle to achieve effective filling and efficient repair of bone defects. Owing to the favourable biocompatibility, hydrogel scaffolds have become a staple material being widely used in bone regeneration. To enhance its osteogenic capacity, the transplantation of bone marrow mesenchymal stem cells (BMSCs) is a frequently employed approach. However, the osteogenic differentiation capacity of unmodified BMSCs within hydrogels is often limited, which restricts their clinical applications. To address this limitation, lentiviral vectors were firstly employed to transfect the key osteogenic transcription factor Runx2 into BMSCs, in this work, to generate Runx2-overexpressing BMSCs ( Runx2 -OE-BMSCs). Subsequently, Runx2 -OE-BMSCs were encapsulated within methacrylated gelatin (GelMA) via 3D bioprinting to fabricate Runx2 -OE-BMSCs loaded hydrogel scaffolds ( Runx2 -OE-BMSCs@GelMA). The in vitro experiments confirmed that the Runx2 -OE-BMSCs@GelMA scaffold exhibits not only excellent biocompatibility but also significantly enhances osteogenic differentiation. Furthermore, the in vivo experiments demonstrated that the Runx2 -OE-BMSCs@GelMA scaffolds could significantly enhance the bone regeneration. In summary, This therapeutic strategy focused on enhancing osteoblast osteogenic activity offers new insights into the treatment of bone defect-related diseases.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: